Use of adjuncts in ahf potassium binders.
-
Upload
drucsamal -
Category
Healthcare
-
view
279 -
download
0
Transcript of Use of adjuncts in ahf potassium binders.
![Page 1: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/1.jpg)
Use of adjuncts in AHF: potassium binders
Alexandre MebazaaDepartment of Anesthesiology and Critical Care
University Hospital Saint Louis – LariboisièreUniversity Paris 7; INSERM – UMR 942
![Page 2: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/2.jpg)
Conflicts of interestHonoraria for lectures:• Orion, AbbVie, Alere, Edwards, Novartis,
Roche, Vifor
Consultancy:• Cardiorentis, Novartis, Sphingotec
![Page 3: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/3.jpg)
Hyperkalemia
• Is increasingly present in cardiovascular area
• Increasing number of diabetes, chronic kidney disease
• Use of RAAS inhibitors
![Page 4: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/4.jpg)
Packham DK et al NEJM 2014
![Page 5: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/5.jpg)
K+K+K+
ZS-9 PROPERTIES
u Unique microporous zirconium silicate compound
u Designed to be selective for K+ trapping
u Insoluble and highly stable
u Non-systemically absorbed
u Builds on long history of Zr use in dialysis and other biomedical applications
ZS-9 Crystal Structure
Average Width of Micropore
Opening 3Å
ZS-9 Selective Potassium Trap
![Page 6: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/6.jpg)
Acute effect of Sodium Zirconiumcyclosilicate
Packham DK et al NEJM 2014Patients: CKD, DM, HF, RAASi
![Page 7: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/7.jpg)
Effect of ZS-9 withdrawal
Packham DK et al NEJM 2014
![Page 8: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/8.jpg)
Kosiborod et al, JAMA 2014
![Page 9: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/9.jpg)
HARMONIZE: Open label phase (1)Rapid drop in serum potassium
Kosiborod et al, JAMA 2014
![Page 10: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/10.jpg)
10Confidential and Proprietary |
Open Label Phase:Consistent Efficacy in All Subgroups
-0.8
-1.5
*P value <0.0001
Error bars represent ±95 confidence intervals Kosiborod et al, JAMA 2014
![Page 11: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/11.jpg)
Harmonize: Randomized phase (2)
Kosiborod et al, JAMA 2014
![Page 12: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/12.jpg)
Adverse events need to be still followed in the future
Kosiborod et al, JAMA 2014
![Page 13: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/13.jpg)
Pitt B et al Eur Heart J 2011
![Page 14: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/14.jpg)
14
Patiromer: Physical & Chemical Properties
Patiromer
Free-flowing powder of small, spherical beads (~100 µm).
Active moiety is a Ca2+ exchange polymer that binds K+ and increases fecal K+ excretion.
Site of action is the lumen of the colon:- K+ is the most abundant cation;- Residence time of the polymer is
the longest.
Light Microscopy Image
Electron Microscopy Image
KayexalatePatiromer
![Page 15: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/15.jpg)
15
Prevention of Hyperkalemia:Patiromer - PEARL-HF Study Design
Spiro 50 mg
1° : Change serum K+
2° : Incidence K+ > 5.5 Spironolactone dose titration
Tolerability/safety
If K+ ≤ 5.1 (day 15)
4-w
eeks
Spiro 25 mg
Subjects with chronic HF, aged 18 or older, clinically indicated to receive spironolactone
1. CKD (eGFR <60 mL/min) and on ≥ 1 ACEI or ARB or βB; or2. Documented Hx hyperK+ < 6 mo*3. K+ > 4.3 – 5.1 mEq/L
* Leading to d/c of RAASi or BB.** No patiromer dose titration.
Placebon ≈ 50
Patiromer 30 g/day**n ≈ 50
4-w
eeks
Pitt B et al Eur Heart J 2011
![Page 16: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/16.jpg)
16
PEARL-HF Primary Efficacy Endpoint: Change From Baseline in Serum K+ (LOCF) by Study Visit
Spironolactone increased to 50 mg/day on Day 15 if K ≤ 5.1
Spironolactone initiated at 25 mg/d on Day 1
*P < 0.01**P < 0.001
***
**** ** **
N=49
N=55
3
Pitt B et al Eur Heart J 2011
![Page 17: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/17.jpg)
17
PEARL-HF: Proportion of Subjects With Serum K > 5.5 mEq/L by eGFR
Pitt B, Anker SD, Bushinsky DA, et al. Eur Heart J. 2011;32(7):820-828.Pitt B. Paper presented at: HFSA Annual Scientific Meeting; September 12-15, 2010; San Diego, CA.
0.250.19
0.390000000000002
0.56
0.07 0.07 0.07
0
mean eGFR =81mL/min
mean eGFR ≥60mL/min
0%
10%
20%
30%
40%
50%
60%
Placebo
N=104 n=76 n=28 n=16
P=0.015P=0.125
P=0.041
P<0.05*
% o
f Sub
ject
s
Pitt B et al Eur Heart J 2011
![Page 18: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/18.jpg)
Weir et al. NEJM 2015
Patients with chronic kidney disease who were receiving RAAS inhibitors with serum K 5.1-6.5 mEq/L
![Page 19: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/19.jpg)
Baseline characteristics
Weir et al. NEJM 2015
![Page 20: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/20.jpg)
20
Relypsa Partiromer: 4-w initial treatment phase
4.0
4.2
4.4
4.6
4.8
5.0
5.2
5.4
5.6
5.8
6.0
Mea
n Se
rum
K+
(mEq
/L)
Mild HK
Moderate/Severe HK
All Subjects
Baseline Week 4Week 2
Secondary Efficacy Endpoint:76% of subjects had serum K+ in the target range
(3.8 to < 5.1 mEq/L) at week 4
Weir et al. NEJM 2015
![Page 21: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/21.jpg)
8-w withdrawal phase: secondary efficacy endpoint
Weir et al. NEJM 2015
![Page 22: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/22.jpg)
Adverse events in the initial phase
Weir et al. NEJM 2015
![Page 23: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/23.jpg)
Treatment of severe hyperkaliemia ?
Kosiborod M et al NEJM 2015
![Page 24: Use of adjuncts in ahf potassium binders.](https://reader034.fdocuments.us/reader034/viewer/2022042706/58a72e081a28ab0d0d8b635b/html5/thumbnails/24.jpg)
In summary
• Hyper K is frequent in cardiovascular conditions
• Two novels compounds are very active to reduce serum K and to prevent any increase under RAASi
• Indications: CKD, HF, optimisation of RAASi ?